SecBot SecBot
8-K ·Filed May 15, 2026

INKT

MiNK Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago SEC0001193125-26-225369
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The EPS beat of 26% vs consensus is largely mechanical given the tiny absolute base (-$0.57 vs -$0.77). The key catalyst is the randomized Phase 2 data for agenT-797 in ARDS expected H2 2026, a binary event in a large unmet need market. Monitor cash runway closely; with $9.5M and quarterly burn of ~$3.9M, the company will likely need additional financing before year-end 2026. The ATS presentation on May 20 could provide a near-term catalyst if data is positive.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating consensus estimates of -$0.77 per share by 26%. The company advanced its lead iNKT cell therapy candidate agenT-797 into a randomized Phase 2 trial for acute lung injury, with preliminary data expected in H2 2026. Cash burn remains disciplined at $9.5M quarter-end, but the company continues to rely on at-the-market equity raises ($3.0M in Q1) and non-dilutive collaborations to fund operations.

Key Financial Metrics

EPS
−$0.57
est −$0.77 · +26.0%
Rating
beat

Key Facts

  • Net loss of $2.7M ($0.57 per share) vs $2.8M ($0.70 per share) in Q1 2025
  • Cash and cash equivalents of $9.5M as of March 31, 2026, down from $13.4M at year-end 2025
  • Repaid $5.2M Agenus convertible note during Q1 2026
  • Raised $3.0M through at-the-market equity sales agreement in Q1 2026
  • Initiated randomized Phase 2 trial for agenT-797 in severe acute lung injury/ARDS
  • Preliminary Phase 2 data expected in second half of 2026
  • Non-dilutive C-Further collaboration provides up to $1.1M for pediatric oncology program
  • ATS conference presentation on agenT-797 in persistent infection scheduled for May 20, 2026

Financial Impact

Net loss improved slightly to $2.7M from $2.8M YoY; cash burn of ~$3.9M in Q1; $9.5M cash runway likely <12 months without additional financing

cashnet lossdilution

Risk Factors

  • Cash runway of ~$9.5M may only fund operations through ~2-3 quarters without additional capital raises
  • Phase 2 ARDS trial is early-stage with binary readout risk; no approved pharmacologic therapies exist in this indication
  • Reliance on at-the-market equity sales for funding creates ongoing dilution for existing shareholders
  • Clinical-stage biotech with no approved products or revenue

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-225369
Document: inkt-ex99_1.htm0001193125-26-225369
Document: 0001193125-26-225369-index-headers.html0001193125-26-225369
Document: 0001193125-26-225369-index.html0001193125-26-225369
Document: 0001193125-26-225369.txt0001193125-26-225369
8-K Data (Synthetic)0001193125-26-225369

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 9h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026